| 1 | Obesity, hypertension and tobacco use associated with le | ft ventricular remodelling and |
|----|---|---|
| 2 | 2 hypertrophy in South African Women: Birth to | 「wenty Plus Cohort |
| 3 | Andrea Kolkenbeck-Ruh ^a , Larske M. Soepnel ^{* a,b} , Simone H. Crou | uch ^a , Sanushka Naidoo ^a , Wayne |
| 4 | Smith ^{c,d} , Shane A. Norris ^{a,e} , Justine Davies ^{a,f} , Lisa J. Ware ^{a,g} | |
| 5 | 5 | |
| 6 | 5 a SAMRC/Wits Developmental Pathways for Health Researc | ch Unit, Faculty of Health Sciences, |
| 7 | 7 University of the Witwatersrand, Johannesburg 2000, Sou | th Africa |
| 8 | b Julius Global Health, Julius Centre for Health Sciences an | d Primary Care, University Medical |
| 9 | O Centre. Utrecht, Utrecht University, Utrecht, The Netherlar | nds. |
| 10 | c Hypertension in Africa Research Team (HART), North-We | st University, South Africa |
| 11 | d South African Medical Research Council: Unit for Hyperter | nsion and Cardiovascular Disease, |
| 12 | 2 North-West University, South Africa | |
| 13 | B e School of Health and Human Development, University of S | Southampton, Southampton, UK |
| 14 | f Institute of Applied Health Research, University of Birming | ham, Birmingham, UK |
| 15 | 5 g DSI-NRF Centre of Excellence in Human Development, U | niversity of the Witwatersrand, |
| 16 | Johannesburg 2000, South Africa. | |
| 17 | 7 | |
| 18 | 3 Correspondence and reprint to: *Larske M. Soepnel. Julius Glob | al Health, Julius Centre for Health |
| 19 | Sciences and Primary Care, University Medical Centre Utrech | t, Utrecht University, Utrecht, The |
| 20 | Netherlands. Postal address: Huispost number: STR 6.131. P.O. I | 3ox 85500, 3508 GA Utrecht. Email: |
| 21 | larske.soepnel@gmail.com | |
| 22 | 2 Abstract | |

Background: Left ventricular hypertrophy (LVH) is a known marker of increased risk in developing
future life-threating CVD, though it is unclear how health risk factors, such as obesity, blood pressure

and tobacco use, associate with left ventricular (LV) remodelling and LVH across generations of
 urban African populations.

Methods: Black female adults (n=123; age: 29-68 years) and their children (n=64; age: 4-10; 55% female) were recruited from the Birth to Twenty Plus Cohort in Soweto, South Africa. Tobacco and alcohol use, physical activity, presence of diabetes mellitus, heart disease and medication were selfreported. Height, weight, and blood pressure were measured in triplicate. Echocardiography was used to assess LV mass at end-diastole, perpendicular to the long axis of the LV and indexed to body surface area to determine LVH.

33 Results: Hypertension and obesity prevalence were 35.8% and 59.3% for adults and 45.3% and 6.3% 34 for children. Self-reported tobacco use in adults was 22.8%. LVH prevalence was 35.8% (n=44) in 35 adults (75% eccentric; 25% concentric), and 6.3% (n=4) in children (all eccentric). Prevalence of 36 concentric remodelling was 15.4% (n=19) in adults and observed in one child. In adults, obesity (OR: 37 2.54 (1.07-6.02; p=0.02) and hypertension (3.39 (1.08-10.62; p=0.04) significantly increased the odds 38 of LVH, specifically eccentric LVH, while concentric LVH was associated with self-reported tobacco 39 use (OR: 4.58 (1.18-17.73; p=0.03; n=11). Although no logistic regression was run within children, of 40 the four children LVH, three had elevated blood pressure and the child with normal blood pressure 41 was overweight.

42 *Conclusions:* The association between obesity, hypertension, tobacco use and LVH in adults, and the 43 6% prevalence of LVH in children, calls for stronger public health efforts to control risk factors and 44 monitor children at who are risk.

45

46 Keywords: left ventricular hypertrophy; ventricular remodelling; Sub-Saharan Africa; Child health;

47 Women's health

48 Background

Despite medical advances, cardiovascular disease (CVD) remains a global health concern affecting more than 37 million individuals [1]. CVD are a leading cause of death globally [2–4]. CVD risk factors, such as hypertension, obesity, type II diabetes mellitus (T2DM), smoking, dyslipidaemia, a sedentary lifestyle, unhealthy diets and excess alcohol intake [4, 5], are increasing in sub-Saharan Africa. South Africa is no exception with rising prevalence of known CVD risk factors, largely as a consequence of urbanisation and marked changes in health behaviour [6–8]. Thus prevention of CVD is an important national public health goal.

Heart failure is the dominant form of CVD in South Africa, of which the main cause is hypertension [9]. Unlike high-income countries, in South Africa heart failure typically affects younger working individuals, and has an in-hospital mortality rate of approximately 8.4%, while 6 months post hospital discharge, fatality rate stands at approximately 26% [10]. As a result of the impact on young, economically active individuals, as well as the high fatality rate, heart failure in South Africa has a disproportional impact on an already fragile economy.

62 A key aspect of the pathological process of CVD, ultimately leading to heart failure and stroke [11, 63 12], is cardiac remodelling. The term is most commonly applied to the left ventricle (LV) in which the 64 chamber changes in size, shape or structure [13]. Left ventricular hypertrophy (LVH), defined as an 65 increase in muscle mass of the LV, is associated with a four-fold increase in heart failure [14-20]. As 66 a result, regression of LVH is a goal of cardiovascular risk reduction [21-24]. Many of the risk factors 67 contributing to the systemic and regional hemodynamic changes that drive the development of LVH 68 [25], are modifiable, including obesity [26], tobacco and alcohol use [27] and elevated blood pressure 69 and hypertension [26].

In South African adult women, there has been a sharp rise in prevalence of overweight/obesity (68%), hypertension (46%), regular alcohol use (17%) [28] and current tobacco smokers (7.6%) [29]. Given the increasing CVD rates, and the restricted access to echocardiography in the public health sector [30], understanding the role of health risk factors in LVH development may have major implications for preventing LVH or interventions for regression of LVH. Furthermore, the growing burden of cardiovascular risk factors could lead to growing burden of LVH and potential increase the burden in offspring. Therefore, the aim of the study was to identify the prevalence of LVH as well as the health
factors associated with LV remodelling and LVH, within black South African adult women and their
pre-pubescent children to inform public health efforts to promote cardiovascular health.

79 Methods

80 Study population

81 Data was collected during a cross-sectional study of vascular health in an existing birth cohort known 82 as the Birth to Twenty Plus (BT20+) Cohort, which started in 1990 (described previously [31]) and 83 now includes three generations. The aim of this study was to investigate the intergenerational transmission of cardiovascular health; the BT20 index female (known as 2nd generation or 2G; aged 84 28-29 years); their birth children or 3rd generation (3G, aged 4-10 years, female or male); and their 85 86 biological mothers or 1st generation (1G, aged 43-68 years, female). For the purpose of the present 87 study, the first and second-generation participants were combined and classified as the "adult group". 88 Thus, 79 families, 237 participants (n=158 adults and n=79 children) were invited to attend for 89 cardiovascular assessment where left ventricular remodelling and hypertrophy were assessed using 90 echocardiography. All data were collected at the Developmental Pathways for Health Research Unit, 91 at Chris Hani Baragwanath Academic Hospital in Soweto. Of the 237 participants recruited, n=187 92 (78.9%) were included in analysis (Figure 1). Trained researchers who spoke the participant's home 93 language explained the study and all participants gave written informed consent (adults) or assent 94 (children aged 7-10 years) prior to data collection. The Human Research Ethics Committee (Medical) 95 of the University of the Witwatersrand approved the protocol (M190263).

96 Health risk factors

97 Tobacco use was assessed using the Global Adult Tobacco Survey [32], alcohol use with the WHO 98 Alcohol Use Disorders (WHO-AUDIT) test [33] and physical activity using the Global Physical Activity 99 Questionnaire (GPAQ) [34]. Self-reported medical history (diabetes mellitus [T2DM), hypertension, 100 high cholesterol, or previous heart disease] and current medication use) was assessed by 101 questionnaire. Thereafter, anthropometry, including height, weight and waist circumference, was 102 measured in triplicate using standardised World Health Organization measurement protocols [35]. 103 Brachial blood pressure (BP) was measured using automated devices (MIT5 for adults; HBP-1300 for children [36]; Omron Healthcare, Kyto, Japan). Following the International Society of Hypertension
(ISH) measurement guidelines [37], participants were seated and asked to rest for at least 5-minutes
prior to measurement of BP in their right arm three times in a quiet room with the monitor facing away
from the participant; there was a 2-minute rest interval between the measurements. The first BP
measurement was discarded and the second and third measurements were averaged for analysis.

109 Echocardiography

110 Transthoracic echocardiography examination was performed by a single echocardiographer, with the 111 Mindray DC-70 Ultrasound system (Mindray, Shenzen China). Measurements of chamber dimensions 112 were taken from 2D mode and left ventricular (LV) mass and relative wall thickness (RWT) were 113 calculated. Linear measurements were made according the American Society of Echocardiography 114 (ASC) Guidelines: Recommendations for Cardiac Chamber Quantification in Adults [38]. LV mass 115 was assessed at end-diastole perpendicular to the long axis of the LV. LVM was calculated according 116 to the Devereus formula: $LVM(q) = 0.8 \times 1.04 ((LVDd+IVSd+LVPWd)^3 - LVDd^3) + 0.6$ where LVDd = 117 left ventricular diastolic diameter; IVSd = intraventricular septal diameter, LVPWd = left ventricular 118 posterior wall thickness in diastole [38]. The left ventricular mass index (LVMI) was calculated as a 119 ratio of LVM indexed to body surface area [38]. The RWT was defined as: 2 x LVPWd/LVDd, where 120 LVPWd = left ventricular posterior wall thickness in diastole; LVDd = left ventricular diastolic diameter 121 [38]. RWT was used to categorise LV mass and the pattern of remodelling. Left ventricular hypertrophy (LVH) was defined as LVMI >95 g/m² for adult women [38] and LVMI >95th percentile 122 123 (88.9 g/m²) for children [39], and eccentric LVH (LVH with RWT ≤0.42) and concentric LVH (LVH with 124 RWT >0.42) as well as concentric remodelling (normal LVMI with RWT >0.42) [38].

125 Data Management

In adults, body mass index (BMI; weight (kg)/height (m)²) was categorised according to the World Health Organisation (WHO) classification as follows: <18.5 kg/m² as underweight; 18.5-24.9 kg/m² as normal; 25-29.9 kg/m² as overweight; and \geq 30 kg/m² as obese [40]. In children (>5 years), age adjusted z-scores for BMI were calculated using the WHO reference and children were categorised as overweight if their BMI z-score was between 1-2, and obese if their BMI z-score was >2 [40]. While in children aged four years, age adjusted z-scores for BMI were categorised as overweight if their BMI zscore was between 2-3, and obese if their BMI z-score was >3 [41]. In adults, hypertension was defined as a BP \geq 140 mmHg systolic or \geq 90 mmHg diastolic or currently taking anti-hypertensive medication; in those who were not on anti-hypertensive medication elevated BP was defined as a BP 130-139 mmHg systolic or 85-89 mmHg diastolic, following the International Society of Hypertension (ISH) Global Hypertension Practice Guidelines [37]. For children, elevated BP was defined as BP \geq 90th percentile for height and age, following the American Academy of Paediatrics Clinical Practice 2017 guidelines [42].

139 Statistical analysis

140 SPSS statistics 25.0 (IBM, Chicago, IL, USA) was used for statistical analysis. Non-normality of data 141 was confirmed using visual inspection of histograms and the Shapiro-Wilk test. Multivariable logistic 142 regression, after checking for multicollinearity by confirming a variance inflation factor of less than five 143 [43], was conducted to examine the relationship between LVH / LV remodelling and the following 144 health factors: age, moderate-vigorous physical activity, sedentary behaviour, obesity, hypertension, 145 previous diagnosis of T2DM, high cholesterol, ever tobacco use and alcohol use. Statistical 146 significance for all analyses was set at p<0.05. Due to the low prevalence of LVH in children, 147 regression analysis was only performed in adults.

148 Results

149 Characteristics of the participants

150 The median age for adult women was 41 years (range 28 to 68 years, n=123) while for children it was 151 7 years (range 4 to 10 years, n=64, 54.7% female) (Table 1). Median BMI was 32.5 kg/m² (IQR: 26.6-152 37.7 kg/m²) and 15.8 kg/m² (IQR: 14.8-17.2 kg/m²) for adults and children respectively, with 59.3% of 153 adults and 6.3% of children classified as obese. Elevated blood pressure (BP) on measurement was 154 found in 41.5% of adults. While 35.8% of adults were classified as hypertensive with 75% on 155 treatment, primarily a diuretic. Nearly sixty percent (59.4%) of children had elevated BP. Of the 123 156 adults, 22.8% were current or past tobacco users (smoking and smokeless tobacco) and 55.3% 157 regularly consumed alcohol. Three adults reported having previous heart disease. A small 158 percentage of adults reported having high cholesterol and T2DM (12.2% and 2.4% respectively).

159 While all participants with self-reported diabetes were on treatment, only 26.7% of adults with high 160 cholesterol were.

The median LVMI was 84.75 (IQR: 71.36-102.33) g/m² and 56.29 (IQR: 47.61-69.17) g/m² for adults and children, respectively **(Table 1)**. Within adults, 48.8% had normal LV geometry, while15.4% had concentric remodelling. The remaining 35.8% had LVH, of which 26.8% had eccentric LVH and 8.9% had concentric LVH. In contrast, 92.2% of children had normal LV geometry, 1.6% had concentric remodelling, 6.3% had eccentric remodelling only, and no concentric LVH was observed.

166 Left ventricular (LV) remodelling and left ventricular hypertrophy (LVH) in adults

167 Table 2, compares characteristics of adults with and without LVH. Overall, women with LVH were 168 significantly older (48 (min: 29, max 66) vs 29 (min: 28, max: 68) years, p=0.04), were more obese 169 (73% vs 52%, p=0.04), and were hypertensive (52% vs 27%, p=0.01) compared to those without 170 LVH. When considering LVH regardless of pattern, after adjusting for age, moderate-vigorous 171 physical activity, sedentary behaviour, obesity, hypertension, T2DM, high cholesterol, ever tobacco 172 use and regular alcohol use, hypertension (OR: 3.39 (1.08-10.62), p=0.04) and obesity (OR: 2.54 173 (1.07-6.02) were significantly associated with LVH. Obesity was the only factor significantly 174 associated with eccentric LVH (OR: 3.46 (1.28-9.37), p=0.02), and reported ever tobacco use was the 175 only factor significantly associated with concentric LVH (OR: 5.06 (1.24-20.69), p=0.02), although the 176 number of adults with this condition was small. No other significant associations were found with LV 177 remodelling in the multivariable logistic regression models (Table 3).

Figure 2, depicts those adults with LVH and the number of health factors. It was observed the prevalence of LVH in adults significantly increased (p=0.002) with the number of health risk factors reported.

181 Left ventricular (LV) remodelling and left ventricular hypertrophy (LVH) in children

Over 90% of children (median age 7 years, range 4-10, 59.3% female) had normal LV geometry despite 59.4% (n=38) having elevated BP, 45.3.% (n=26) being hypertensive and 23.4% (n=15) being overweight or obese (**Table 1**). Of the four children with LVH (all eccentric LVH), three had elevated BP and were normal weight, while the fourth child had normal BP, however, was overweight. **Figure** 2, depicts those children with LVH and the number of health factors, in which 3 out of the 4 children
with LVH has one health factor.

188

189 Discussion

190 In the present study, we assessed the prevalence of LVH in black South African women and their 191 children/grandchildren and health factors associated with LVH. We found a high prevalence of LVH in 192 South African black adult women (28-68 years), with over a guarter having eccentric LVH. Obesity 193 and hypertension, two modifiable health factors, were associated with eccentric LVH, while self-194 reported tobacco use was related to concentric LVH. Of the women with LVH, half of the women had 195 three or four health risk factors. Despite the small sample size, 6% of children aged 4-10 years had 196 eccentric LVH, of which three had elevated blood pressure (BP). The current study highlights that 197 multiple factors significantly drive the development of LVH in adult women. In addition, although only 198 four children had LVH, the high prevalence of elevated BP and children is concerning and aids in 199 supporting ongoing calls for prevention efforts, particularly for youth.

200 In African countries, CVD is increasing rapidly. LVH is a known marker of increased risk for 201 developing future life-threating CVD and there is evidence to suggest that LVH is higher in black 202 populations of African descent [44]. Various studies conducted over the past decade in Sub-Saharan 203 Africa have reported the prevalence of LVH among women (mean age range: 43-57 years) to vary 204 from 19.9% to 44.5% [19, 45-47], which is consistent with the current study's findings (35.8% of 205 South African women; mean age: 41.3 years). Our estimates are, however, higher than previously 206 reported South African data by Maseko et al and Libhaber et al (LVH prevalence of 19.9% and 21.7% 207 respectively, despite similar ages (44 years)) [45, 46]. This increase in LVH prevalence may be, in 208 part, due to increasing risk cardiovascular risk factors from 2013. However, although the populations 209 in both studies were similar to that of the current study (both black South African), the methodology 210 was different. Both studies used LVM indexed to height^{2.7} [45, 46], whilst the current study used LVM 211 indexed to body surface area. However, when indexing LVM to height^{2.7}, the current study's 212 prevalence increased slightly from 35.8% (n=44) to 38.2% (n=47) (data not shown). To date, there 213 remains controversy around the method to index LVM to accurately identify LVH within individuals in

the Southern African region. Due to the high prevalence of stunting observed within the South African population [48, 49], and LVM indexed to body surface area was identified as the most appropriate method so as not to under or overestimate LVH calculated by height^{2.7}. This, in conjunction with the guidelines from *The American Society of Echocardiography Recommendations for Cardiac Chamber Quantification in Adults* [38], further supports the use of body surface area over height^{2.7}.

219 LVH is a compensatory response to cardiac insult through interactions between pressure and/or 220 volume overload [50]. Increasing age, hypertension, and obesity are the three main cardiovascular 221 risk factors that drive pressure and volume overload within the heart [50, 51]. The current study found 222 that obesity and hypertension were associated with a two-fold and a three-fold respective risk of 223 developing LVH (irrespective of type), and a three-fold risk of developing eccentric LVH. This is in line 224 with results from the Framingham study that suggest a 7% increase for risk for developing LVH per 225 one unit increase of body mass index (BMI) in women [52, 53]. Furthermore, there is a three-fold risk 226 of developing CVD in individuals with BP ≥ 130/90 mmHg compared to individuals with BP < 120/80 227 mmHg [54]. In South Africa, approximately 68% of women (≥15 years) are overweight or obese [55] 228 and hypertension is currently reported as one of the most common causes of CVD [19, 55]. Current 229 understanding of hemodynamic alterations accompanying obesity and hypertension suggests that 230 they drive an increase in LV filling and stroke volume, which specifically causes LV dilation and 231 eccentric, rather than concentric, LVH [26, 56-59]. However, studies by Woodiwiss et al [60] and 232 Avelar et al [61] found that adiposity was associated with concentric LVH, independently of BP. Our 233 smaller sample size (n=123, of which 11 had concentric LVH) may explain the lack of an association 234 between obesity and concentric LVH in our study. In addition, due to the confounding effects of both 235 hypertension and obesity, their interactions and duration within the same individual left ventricular 236 remodelling and hypertrophy may be different. Therefore, before definitive conclusions can be 237 reached, within this population, further studies investigating interactions of obesity and hypertension 238 are required.

Along with obesity and hypertension, smoking prevalence in South Africa is currently on the rise [55]. There is sound evidence that smoking impacts cardiac structure and function [62, 63], and results from other studies suggest significant increases in LVMI, and thus LVH, in individuals who smoke compared to those that don't [62, 64, 65]. Similarly, although our sample of women that had concentric LVH was small, our data showed an association between smoking and concentric LVH.

244 The currently study found a high prevalence of elevated blood pressure (59.4%) in children. Despite 245 this high prevalence it may seem encouraging that only four children had LVH. However, of those four 246 children that had LVH, three had elevated blood pressure and the one child that was normotensive 247 was overweight. Thus, following the same pattern observed in adults, that the rising health risk 248 factors, namely elevated blood pressure and weight gain in children reflect more a pessimistic outlook 249 and are the driving factors behind CVD risk in children that also may persist into adulthood. Further 250 supporting calls for earlier identification of those that are at risk and interventions where necessary, 251 especially within children.

252 A strength of this study is the indexing of LVM to body surface area. Indexing LVM to body height may 253 result in error in LVH classification due to the prevalence of stunting in this population [48, 49]. A 254 limitation of the present study was the ages within the adult group. As this study recruited from within 255 an existing birth cohort with all index children recruited at birth in 1990, these 'children' were all 29 256 years old adults at the time of the measurements, resulting in a clustering of adults around 29 years 257 with their parents aged 45-65 years. Furthermore, we relied on self-reported data for medical history 258 and health behaviours. Given the potential association between self-reported tobacco use and LVH in 259 adults, analysing biomarkers of tobacco exposure could be a useful next step. As the low frequency of 260 children with LVH prevented further statistical analysis, additional studies with larger sample sizes are 261 needed to assess potential relationships between modifiable health behaviours and LVH.

262 Conclusions

In conclusion, the results have highlighted the need for specific call to action polices around obesity, hypertension and tobacco in adult women and target intervention around weight management and elevated BP in children. Due to the high risk of developing LVH due to obesity and hypertension, specific interventions, prior to the development of obesity and hypertension (i.e. overweight and elevated BP individuals), are needed to prevent the development of LVH, and in cases where LVH is evident, regress LVH. As obesity and hypertension have both additive and interactive effects on LVH development, **both** weight loss programs and BP lowering medications (such as hydrochlorothiazide

- 270 [66, 67]) are required to achieve appropriate LVH regression, particular in this population where
- 271 obesity and hypertension is prevalent.
- 272 Abbreviations
- 273 ASC, American Society of Echocardiography
- 274 BMI, body mass index
- 275 BT20+, Birth to Twenty Plus Cohort
- 276 BP, blood pressure
- 277 CI, confidence interval
- 278 CVD, cardiovascular disease
- 279 GPAQ, global physical activity questionnaire
- 280 IQR, interquartile range
- 281 ISH, International Society of Hypertension
- 282 IVSd, intraventricular septal diameter
- 283 LVDd, left ventricular diastolic diameter
- 284 LVPWd, left ventricular posterior wall thickness in diastole
- 285 LV, left ventricular
- 286 LVH, left ventricular hypertrophy
- 287 LVM, left ventricular mass
- 288 LVMI, left ventricular mass index
- 289 MVPA, moderate-vigorous physical activity
- 290 OR, odds ratio
- 291 RWT, relative wall thickness

- 292 T2DM, type II diabetes mellitus
- 293 WHO, world health organisation
- 294 WHO-AUDIT, WHO Alcohol Use Disorders
- 295 1G, first generation
- 296 2G, second generation
- 3G, third generation
- 298 Declarations

299 Ethical approval and consent to participate

- 300 Written informed consent was provided by all women and their children / grandchildren prior to their
- 301 inclusion in the study and ethical approval was obtained from the University of the Witwatersrand's
- 302 Research Ethics Committee (Medical) with ethical clearance number M190263
- 303 Consent for publication
- 304 Not applicable
- 305 Availability of data and materials
- 306 The datasets used and/or analysed during the current study are available from the corresponding
- 307 author on reasonable request
- 308 Competing interest
- 309 The authors declare that they have no competing interests.
- 310 Funding
- 311 This study was supported by a Wellcome Trust Seed Award to Lisa Ware (214082/Z/18/Z)
- 312 Author's contributions
- 313 AKR and LJW, conceptualised and designed the study. AKR was responsible for data management,
- data analysis and wrote the original draft. AKR, LMS, SHC, SN, WS, SAN, JD, LJW, contributed to

315 interpretation of data and critical review of manuscript. LW was the Principal Investigator of the 316 project. All authors gave final approval of the version to be submitted.

317 Acknowledgements

- 318 Funding support from the South African Medical Research Council, Wellcome Trust, and DSI-NRF
- 319 Centre of Excellence in Human Development at the University of the Witwatersrand, Johannesburg,
- 320 South Africa for the Birth to Twenty Plus Cohort.

321 References

- 322 1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nature Reviews Cardiology.
- 323 2016;13:368–78. doi:10.1038/nrcardio.2016.25.
- 324 2. Bradshaw D, Groenewald P, Laubscher R, Nannan N, Nojilana B, Norman R, et al. Initial burden of
- disease estimates for South Africa, 2000 □: original article. Samj. 2003.
- 326 3. Bhatia RS, Tu J V., Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with
- 327 preserved ejection fraction in a population-based study. N Engl J Med. 2006.
- 4. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and
- 329 stroke statistics-2015 update : A report from the American Heart Association. Circulation. 2015.
- 330 5. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease
- 331 pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from
- the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009.
- 333 6. Steyn K, Damasceno A. Lifestyle and Related Risk Factors for Chronic Diseases. 2006.
- 7. Rayner B. Hypertension: Detection and management in South Africa. Nephron Clinical Practice.2010.
- 336 8. Maredza M, Bertram MY, Tollman SM. Disease burden of stroke in rural South Africa: An estimate
- of incidence, mortality and disability adjusted life years. BMC Neurol. 2015.
- 338 9. Hitzeroth J, Mpe M, Klug E, Ranjith N, Sliwa K, Steingo L, et al. 2020 Heart Failure Society of
- 339 South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure

- 340 Guidelines. S Afr Med J. 2020;110:13057.
- 10. Szymanski PZ, Badri M, Mayosi BM. Clinical characteristics and causes of heart failure,
- 342 adherence to treatment guidelines, and mortality of patients with acute heart failure: Experience at
- 343 Groote Schuur Hospital, Cape Town, South Africa. South African Med J. 2018;108:94–8.
- 11. Bots ML, Nikitin Y, Salonen JT, Elwood PC, Malyutina S, Freire de Concalves A, et al. Left
- 345 ventricular hypertrophy and risk of fatal and non-fatal stroke. EUROSTROKE: A collaborative study
- among research centres in Europe. J Epidemiol Community Health. 2002;56 SUPPL. 1:i8.
- 347 doi:10.1136/jech.56.suppl_1.i8.
- 348 12. Ranganai E, Matizirofa L. An analysis of recent stroke cases in South Africa: Trend, seasonality
- and predictors. South African Med J. 2020;110:92–9.
- 350 13. Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and Cardiac Remodeling in Adults:
- 351 Mechanisms and Clinical Implications. Prog Cardiovasc Dis. 2018;61:114–23.
- 352 doi:10.1016/j.pcad.2018.07.012.
- 353 14. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic Implications of
- 354 Echocardiographically Determined Left Ventricular Mass in the Framingham Heart Study. N Engl J
- 355 Med. 1990;322:1561–6. doi:10.1056/nejm199005313222203.
- 15. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP.
- 357 Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The
- 358 Framingham heart study. Ann Intern Med. 1988;108:7–13.
- 359 16. Wright GA, Ang DS, Stonebridge PA, Belch JJ, Struthers AD. Left ventricular hypertrophy is
- 360 present in one-half of newly-diagnosed peripheral arterial disease patients. J Hypertens.
- 361 2007;25:463–9. doi:10.1097/HJH.0b013e328010d64b.
- 362 17. Katholi RE, Couri DM. Left ventricular hypertrophy: Major risk factor in patients with hypertension:
- 363 Update and practical clinical applications. International Journal of Hypertension. 2011;2011.
- 364 18. Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general
- 365 population. The Tromso Study. Eur Heart J. 1999;20:429–38. doi:10.1053/euhj.1998.1314.

- 366 19. Baldo MP, Gonçalves MA, Capingana DP, Magalhães P, da Silva ABT, Mill JG. Prevalence and
- 367 Clinical Correlates of Left Ventricular Hypertrophy in Black Africans. High Blood Press Cardiovasc
- 368 Prev. 2018;25:283–9. doi:10.1007/s40292-018-0267-y.
- 369 20. Brady TM. The Role of Obesity in the Development of Left Ventricular Hypertrophy Among
- 370 Children and Adolescents. Current Hypertension Reports. 2016;18:1–7. doi:10.1007/s11906-015-
- 371 0608-3.
- 372 21. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic
- 373 significance of left ventricular mass change during treatment of hypertension. J Am Med Assoc.
- 374 2004;292:2350–6. doi:10.1001/jama.292.19.2350.
- 22. Pierdomenico S, ... DL-A journal of, 2008 undefined. Regression of echocardiographic left
- 376 ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential
- 377 hypertension. academic.oup.com. 2008. doi:10.1038/ajh.2008.2.
- 378 23. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive
- treatment: A meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084–91.
- 380 24. Lønnebakken MT, Izzo R, Mancusi C, Gerdts E, Losi MA, Canciello G, et al. Left ventricular
- 381 hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania salute
- 382 network). J Am Heart Assoc. 2017;6. doi:10.1161/JAHA.116.004152.
- 383 25. Messerli FH, Ketelhut R. Left ventricular hypertrophy: an independent risk factor PubMed. J
- 384 Cardiovasc Pharmacol. 1991;:17 Suppl 4:S59-66; discussion S66-7.
- 385 https://pubmed.ncbi.nlm.nih.gov/1726010/. Accessed 26 Feb 2021.
- 386 26. Woodiwiss AJ, Norton GR. Obesity and Left Ventricular Hypertrophy: The Hypertension
- 387 Connection. Curr Hypertens Rep. 2015;17.
- 27. Park SK, Moon K, Ryoo JH, Oh CM, Choi JM, Kang JG, et al. The association between alcohol
- 389 consumption and left ventricular diastolic function and geometry change in general Korean population.
- Eur Heart J Cardiovasc Imaging. 2018;19:271–8. doi:10.1093/ehjci/jex091.
- 391 28. National Department of Health (NDoH), Statistics South Africa (Stats SA), South African Medical
- 392 Research Council (SAMRC) and I, Survey H. South Africa Demographic and Health Survey 2016:

393 Key Indicators. 2017. www.statssa.gov.za. Accessed 19 May 2021.

- 394 29. Reddy P, Zuma K, Shisana O, Jonas K, Sewpaul R. Prevalence of tobacco use among adults in
- 395 South Africa: Results from the first South African national health and Nutrition Examination Survey.
- 396 South African Med J. 2015;105:648–55. doi:10.7196/SAMJnew.7932.
- 30. Bedeker WF, Lachman AS, Borkum M, Hellenberg D, Cupido CS. Impact of transthoracic
- echocardiography at district hospital level. South African Med J. 2015;105:817–22.
- 399 31. Richter L, Norris S, Pettifor J, Yach D, Cameron N. Europe PMC Funders Group Cohort Profile ::
- 400 Mandela 's children : The 1990 birth to twenty study in South Africa. Int J Epidemiol. 2007;36:504–
- 401 11.
- 402 32. Kalsbeek WD, Bowling JM, Hsia J, Mirza S, Palipudi KM, Asma S. The Global Adult Tobacco
- 403 Survey (GATS): Sample Design and Related Methods. 2010;:1–15. papers://c0f50874-1acc-4627-
- 404 879e-caecd2247efe/Paper/p711.
- 405 33. SAUNDERS JB, AASLAND OG, BABOR TF, DE LA FUENTE JR, GRANT M. Development of the
- 406 Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of

407 Persons with Harmful Alcohol Consumption-II. Addiction. 1993;88:791–804.

- 408 34. Cleland CL, Hunter RF, Kee F, Cupples ME, Sallis JF, Tully MA. Validity of the Global Physical
- 409 Activity Questionnaire (GPAQ) in assessing levels and change in moderate-vigorous physical activity
- 410 and sedentary behaviour. BMC Public Heal 2014 141. 2014;14:1–11. doi:10.1186/1471-2458-14-
- 411 1255.
- 412 35. de Onis M, Garza C, Victora CG, Onyango AW, Frongillo EA, Martines J. The WHO Multicentre
- 413 Growth Reference Study: Planning, study design, and methodology. Food Nutr Bull. 2004;25 1
- 414 SUPPL. 1:15–26.
- 415 36. Meng L, Zhao D, Pan Y, Ding W, Wei Q, Li H, et al. Validation of Omron HBP-1300 professional
- 416 blood pressure monitor based on auscultation in children and adults. BMC Cardiovasc Disord.
- 417 2016;16:1–5. doi:10.1186/s12872-015-0177-z.
- 418 37. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International

- 419 Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;:1334–57.
- 420 38. Orsinelli DA, Armour A, De Cara J, Fey B, Frommelt P, Lopez-Mattei J, et al. the American
- 421 Society of Echocardiography Recommendations for Cardiac Chamber Quantification in Adults. J Am
- 422 Soc Echocardiogr. 2015;28 July:1–39.
- 423 39. Simpson JM, Savis A, Rawlins D, Qureshi S, Sinha MD. Incidence of left ventricular hypertrophy
- 424 in children with kidney disease: Impact of method of indexation of left ventricular mass. Eur J
- 425 Echocardiogr. 2010;11:271–7.
- 426 40. WHO/Europe | Nutrition Body mass index BMI. https://www.euro.who.int/en/health-
- 427 topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. Accessed 1 Jul 2020.
- 428 41. WHO. Body mass index-for-age (BMI-for-age). https://www.who.int/toolkits/child-growth-
- 429 standards/standards/body-mass-index-for-age-bmi-for-age. Accessed 17 Mar 2021.
- 430 42. Flynn JT, Falkner BE. New clinical practice guideline for the management of high blood pressure
- 431 in children and adolescents. Hypertension. 2017;70:683–6.
- 432 43. Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72:558–69.
- 433 44. Kamath S, Markham D, Drazner MH. Increased prevalence of concentric left ventricular
- 434 hypertrophy in African-Americans: Will an epidemic of heart failure follow? Heart Fail Rev.
- 435 2006;11:271–7.
- 436 45. Maseko MJ, Woodiwiss AJ, Libhaber CD, Brooksbank R, Majane OHI, Norton GR. Relations
- 437 between white coat effects and left ventricular mass index or arterial stiffness: role of nocturnal blood
- 438 pressure dipping. Am J Hypertens. 2013;26:1287–94.
- 439 46. Libhaber CD, Norton GR, Maseko MJ, Majane OHI, Millen AME, Maunganidze F, et al.
- 440 Relationship between inappropriate left ventricular hypertrophy and ejection fraction independent of
- 441 absolute or indexed mass in a community sample of black African ancestry. J Hypertens.
- 442 2013;31:169–76.
- 443 47. Isaac Kofi O, Emmanuel AA. Determinants of Left Ventricular Hypertrophy in Hypertensive
- 444 Patients seen in a Teaching Hospital in Ghana. J Hypertens Open Access. 2017;06:1–7.

- 445 48. Willey BA, Cameron N, Norris SA, Pettifor JM, Griffiths PL. Socio-economic predictors of stunting
- 446 in preschool children A population-based study from Johannesburg and Soweto. South African Med447 J. 2009.
- 448 49. Nyati LH, Pettifor JM, Norris SA. The prevalence of malnutrition and growth percentiles for urban
 449 South African children. BMC Public Health. 2019;19:1–13.
- 450 50. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327–34.
- 451 doi:10.1161/CIRCULATIONAHA.108.845792.
- 452 51. Aronow WS. Hypertension and left ventricular hypertrophy. Annals of Translational Medicine.
- 453 2017;5. doi:10.21037/atm.2017.06.14.
- 454 52. Horwich TB, Fonarow GC. Glucose, Obesity, Metabolic Syndrome, and Diabetes. Relevance to
- 455 Incidence of Heart Failure. Journal of the American College of Cardiology. 2010;55:283–93.
- 456 doi:10.1016/j.jacc.2009.07.029.
- 457 53. Hamzeh N, Ghadimi F, Farzaneh R, Hosseini SK. Obesity, heart failure, and obesity paradox.
- Journal of Tehran University Heart Center. 2017;12:1–5. http://jthc.tums.ac.ir. Accessed 19 May 2021.
- 459 54. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of High-
- 460 Normal Blood Pressure on the Risk of Cardiovascular Disease. N Engl J Med. 2001;345:1291–7.
- 461 doi:10.1056/nejmoa003417.
- 462 55. National Department of Health (NDoH), Statistics South Africa (Stats SA), South African Medical
- 463 Research Council (SAMRC) and I. South Africa Demographic andd Health Survey 2016. 2019.
- 464 56. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure:
- 465 Epidemiology, pathophysiology, clinical manifestations, and management. Translational Research.
- 466 2014;164:345–56.
- 467 57. Nauta JF, Hummel YM, Tromp J, Ouwerkerk W, van der Meer P, Jin X, et al. Concentric vs.
- 468 eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics,
- 469 pathophysiology and response to treatment. Eur J Heart Fail. 2019;:1–9.
- 470 58. Avelar E, Cloward T V., Walker JM, Farney RJ, Strong M, Pendleton RC, et al. Left ventricular

- 471 hypertrophy in severe obesity: Interactions among blood pressure, nocturnal hypoxemia, and body
- 472 mass. Hypertension. 2007;49:34–9. doi:10.1161/01.HYP.0000251711.92482.14.
- 473 59. Aurigemma GP, De Simone G, Fitzgibbons TP. Cardiac remodeling in obesity. Circ Cardiovasc
- 474 Imaging. 2013;6:142–52.
- 475 60. Woodiwiss AJ, Libhaber CD, Majane OHI, Libhaber E, Maseko M, Norton GR. Obesity promotes
- 476 left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of
- 477 blood pressure. Am J Hypertens. 2008;21:1144–51.
- 478 61. Avelar E, Cloward T V., Walker JM, Farney RJ, Strong M, Pendleton RC, et al. Left ventricular
- 479 hypertrophy in severe obesity: Interactions among blood pressure, nocturnal hypoxemia, and body
- 480 mass. Hypertension. 2007;49:34–9. doi:10.1161/01.HYP.0000251711.92482.14.
- 481 62. Fidelix MP, Tanni SE, Roscani MG, Mesquita CB, Schelini KN de M, Polegato BF, et al. Vitamin D
- role in smoking women and cardiac remodeling. Nutrire. 2016;41:1–7. doi:10.1186/s41110-016-0012-
- 483 z.
- 484 63. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease.
- 485 Expert Review of Cardiovascular Therapy. 2008;6:883–95. doi:10.1586/14779072.6.6.883.
- 486 64. Leigh JA, Kaplan RC, Swett K, Balfour P, Kansal MM, Talavera GA, et al. Smoking intensity and
- 487 duration is associated with cardiac structure and function: The ECHOcardiographic Study of
- 488 Hispanics/Latinos. Open Hear. 2017;4:1–12.
- 489 65. Kaplan A, Abidi E, Ghali R, Booz GW, Kobeissy F, Zouein FA. Functional, Cellular, and Molecular
- 490 Remodeling of the Heart under Influence of Oxidative Cigarette Tobacco Smoke. Oxid Med Cell
- 491 Longev. 2017;2017.
- 492 66. Roush GC, Abdelfattah R, Song S, Ernst ME, Sica DA, Kostis JB. Hydrochlorothiazide vs
- 493 chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left
- 494 ventricular hypertrophy: A systematic review and meta-analysis. J Clin Hypertens. 2018;20:1507–15.
- 495 doi:10.1111/jch.13386.
- 496 67. Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left
- 497 ventricular hypertrophy in hypertension: A meta-analysis. Am J Hypertens. 2010;23:876–81.

20 - LVH in South African women and children

498 doi:10.1038/ajh.2010.80.




Figure 1. Study flow diagram




Figure 2. Percentage of South African adult women and children with left ventricular hypertrophy (LVH) according to the number of health factors. Health behaviours for women included: obesity, hypertension, self-reported type II diabetes mellitus, self-reported high cholesterol, tobacco use, and alcohol consumption. Health behaviours for children included: obesity, elevated blood pressure, whether their mother and or grandmother use tobacco.

Table 1. Characteristics of the adults and children (n=187)

| | Adults (n=123) | Children (n=64) |
|---|---------------------|-------------------|
| Age (years), minimum and maximum | 41.3 (28-68) | 6.9 (4-10) |
| Females, n (%) | 123 (100) | 35 (55) |
| Anthropometry | | |
| Body mass index (kg/m²) | 32.5 (26.6-37.7) | 15.8 (14.8-17.2) |
| Underweight [#] (BMI≤18 or <-2SD in children), n (%) | 1 (0.8) | 8 (12.5) |
| Normal [#] (BMI: 18-25 or -2 to 1SD in children), n (%) | 18 (14.6) | 41 (64.1) |
| Overweight [#] (BMI: 25-30 or 1 to 2SD in children), n (%) | 31 (25.2) | 11 (17.2) |
| Obese [#] (BMI≥30 or >2SD in children), n (%) | 73 (59.3) | 4 (6.3) |
| Blood pressure | | |
| Systolic BP (mmHg) | 113 (106-125) | 107 (99-113) |
| Diastolic BP (mmHg) | 79 (73-86) | 70 (64-75) |
| Heart rate (bpm) | 73 (66-81) | 88 (79-98) |
| | 7 (5.7) | 38 (59.4) |
| Elevated BP*, n (%) Hypertension*, n (%) | 44 (35.8) | 00 (00.4) |
| Of which, on medication | 33 (75.0) | |
| , | 20 (60.6) | _ |
| Hydrochlorothiazide, n (%) | 20 (00.0) | - |
| Medical history | | |
| Previously diagnosed diabetes mellitus, n (%) | 3 (2.4) | - |
| Previously diagnosed high cholesterol, n (%) | 15 (12.2) | - |
| Previous heart disease, n (%) | 3 (2.4) | - |
| Tobacco & alcohol use, n (%) | | |
| Ever used tobacco (smoke and/or smokeless) | 28 (22.8) | - |
| Of which, currently smoke tobacco | 9 (32.1) | - |
| Of which, currently use smokeless tobacco | 18 (64.3) | - |
| Of which, previously smoked tobacco | 1 (3.6) | |
| Regular alcohol use | 68 (55.3) | - |
| Of which, have ≥6 drinks/day | | |
| Never | 28 (41.2) | |
| Infrequently (monthly or less) | 35 (51.5) | - |
| Frequently (weekly or daily) | 5 (7.4) | - |
| Physical activity | | |
| Moderate-vigorous physical activity (min/week) | 525 (160-1605) | - |
| Sedentary behaviour (min/week) | 690 (180-1140) | - |
| Left ventricular geometry | | |
| Left ventricular mass (g) | 155.9 (126.5-199.6) | 51.6 (42.9-65.5) |
| Left ventricular mass indexed (LVMI) to BSA (g/m ²) | 84.8 (71.4-102.3) | 56.29 (47.6-69.2) |
| Relative wall thickness | 0.35 (0.31-0.42) | 0.27 (0.22-0.32) |
| Normal geometry | 60 (48.8) | 59 (92.2) |
| Concentric remodelling, n (%) | 19 (15.4) | 1 (1.6) |
| Left ventricular hypertrophy (LVH) – All, n (%) | 44 (35.8) | 4 (6.3) |
| Eccentric LVH, n (%) | 33 (26.8) | 4 (6.3) |
| Concentric LVH, n (%) | 11 (8.9) | - |

Data presented as median and interquartile range, unless otherwise indicated. BMI, body mass index; BP, blood pressure; bpm, beats per minute. LVMI, left ventricular mass index; BSA, body surface area; LVH, left ventricular hypertrophy."Hypertension and elevated BP categories defined according to the ISH guidelines [37] for adults and the Academy of Pediatrics Clinical Practice 2017 guidelines [42] for children. "BMI categories classifies according to the WHO guidelines [40] for adults and children respectively.

Table 2. Sociodemographic characteristics of the women adults with and without left ventricular hypertrophy

| | With LVH | Without LVH | p-value |
|--|------------------|------------------|---------|
| n | 44 | 79 | - |
| Age (years), minimum and maximum | 48 (29,66) | 29 (28,68) | 0.04 |
| Anthropometry | | | |
| Body mass index (kg/m ²) | 34.9 (28.9-40.4) | 30.3 (25.9-34.6) | 0.01 |
| Underweight [#] (BMI≤18), n (%) | 1 (2.3) | 0 | - |
| Normal [#] (BMI: 18-25) n (%) | 5 (11.4) | 13 (16.5) | 0.10 |
| Overweight [#] (BMI: 25-30), n (%) | 6 (13.6) | 25 (31.60 | 0.03 |
| Obese [#] (BMI≥30), n (%) | 32 (72.7) | 41 (51.9) | 0.04 |
| Blood pressure | | | |
| Systolic BP (mmHg) | 119 (108-129) | 111 (104-123) | 0.16 |
| Diastolic BP (mmHg) | 74 (72-90) | 79 (73-84) | 0.99 |
| Heart rate (bpm) | 56 (65-81) | 74 (66-82) | 0.55 |
| Elevated BP*, n (%) | 3 (6.8) | 4 (5.1) | 0.70 |
| Hypertension*, n (%) | 23 (52.3) | 21 (26.6) | 0.01 |
| Of which, on medication | 16 (69.6) | 17 (80.9) | 0.001 |
| Hydrochlorothiazide, n (%) | 12 (75.0) | 8 (47.1) | 0.02 |
| Medical history | | | |
| Previously diagnosed diabetes mellitus, n (%) | 3 (6.8) | 0 | 0.09 |
| Previously diagnosed high cholesterol, n (%) | 6 (13.6) | 9 (11.4) | 0.48 |
| Previous heart disease, n (%) | 1 (2.3) | 0 | - |
| Tobacco & alcohol use, n (%) | | | |
| Ever used tobacco (smoke and/or smokeless) | 13 (29.5) | 15 (19.0) | 0.19 |
| Of which, currently smoke tobacco | 4 (9.1) | 5 (6.30 | 0.72 |
| Of which, currently use smokeless tobacco | 8 (18.2) | 10 (12.7) | 0.43 |
| Of which, previously smoked tobacco | 1 (2.5) | 0 | 0.35 |
| Ever used alcohol | 23 (52.3) | 45 (57.0) | 0.71 |
| Of which, have ≥6 drinks/day | | | |
| Never | 11 (47.8) | 17 (37.8) | 0.04 |
| Infrequently (monthly or less) | 10 (43.5) | 25 (55.6) | 0.04 |
| Frequently (weekly or daily) | 2 (8.7) | 3 (6.7) | 0.06 |
| Physical activity | | | |
| Moderate-vigorous physical activity (min/week) | 600 (60-1823) | 510 (180-1215) | |
| Sedentary behaviour (min/week) | 509 (19-960) | 720 (210-1320) | |

Data presented as median and interquartile range, unless otherwise indicated. BMI, body mass index; BP, blood pressure; bpm, beats per minute; LVH, left ventricular hypertrophy. *Hypertension and elevated BP categories defined according to the ISH guidelines [37]. [#]BMI categories classifies according to the WHO guidelines [40]. p<0.05 was considered significant.

Table 3. Multivariable adjusted associations between health risk factors and left ventricular remodelling and left ventricular hypertrophy in adults

| Models with \rightarrow | LV remodelling | | LVH (all patterns) | | Eccentric LVH | | Concentric LVH | |
|----------------------------|-------------------|---------|--------------------|---------|-------------------|---------|-------------------|---------|
| | n=19 | | n=44 | | n=33 | | n=11 | |
| | OR (95%Cl) | p-value | OR (95%CI) | p-value | OR (95%Cl) | p-value | OR (95%Cl) | p-value |
| Age | 0.99 (0.94-1.05) | 0.77 | 0.99 (0.95-1.04) | 0.76 | 0.98 (0.94-1.03) | 0.37 | 1.03 (0.96-1.10) | 0.46 |
| MVPA | 1.00 (0.99-1.00) | 0.33 | 1.00 (1.00-1.00) | 0.29 | 1.00 (1.00-1.00) | 0.37 | 1.00 (1.00-1.001) | 0.62 |
| Sedentary behaviour | 1.00 (1.00-1.001) | 0.42 | 1.00 (0.99-1.00) | 0.47 | 1.00 (0.99-1.00) | 0.25 | 1.00 (1.00-1.001) | 0.49 |
| Obesity [¥] | 0.58 (0.19-1.73) | 0.33 | 2.54 (1.07-6.02) | 0.03* | 3.46 (1.28-9.37) | 0.02* | 1.03 (0.24-4.32) | 0.97 |
| Hypertension [#] | 3.44 (0.80-14.82) | 0.09 | 3.39 (1.08-10.62) | 0.04* | 3.83 (1.10-13.31) | 0.03 | 1.23 (0.17-8.96) | 0.84 |
| T2DM_ | 1.92 (0.47-7.78) | 0.36 | 1.05 (0.29-3.86) | 0.94 | 0.82 (0.18-3.72) | 0.79 | 1.41 (0.22-9.21) | 0.72 |
| High cholesterol_ | 4.56 (0.50-41.24) | 0.18 | 1.33 (0.39-4.55) | 0.65 | 1.61 (0.42-6.20) | 0.49 | 0.73 (1.00-5.40) | 0.76 |
| Tobacco ^{\$} use_ | 1.14 (0.34-3.84) | 0.83 | 1.87 (0.73-4.80) | 0.192 | 0.84 (0.29-2.41) | 0.75 | 5.06 (1.24-20.69) | 0.02* |
| Alcohol use_ | 1.33 (0.44-3.99) | 0.61 | 1.22 (0.51-2.94) | 0.656 | 0.74 (0.29-1.92) | 0.54 | 3.38 (0.68-16.79) | 0.14 |

OR, odds ratio; CI, confidence interval; MVPA, moderate-vigorous physical activity; LV, left ventricular; LVH, left ventricular hypertrophy; T2DM, type 2 diabetes mellitus. * As defined as a body mass index (BMI) ≥30 kg/m² according to the WHO guidelines [40]. [#]Hypertension as defined by the ISH guidelines [37]. Self-reported. ^{\$}Smoking and smokeless tobacco. * p<0.05 was considered significant.